Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)

被引:55
作者
Lakhman, SS
Ghosh, D
Blanco, JG
机构
[1] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Hauptman Woodward Med Res Inst, Dept Biol Struct, Buffalo, NY USA
[3] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[4] Roswell Pk Canc Inst, Therapeut Program, Buffalo, NY 14263 USA
关键词
D O I
10.1124/dmd.104.002006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human carbonyl reductase (CBR) activity accounts for a significant fraction of the metabolism of endogenous and xenobiotic carbonyl compounds. It is possible that genetic polymorphisms in CBR1 and CBR3 are key for the wide interindividual variability in the disposition of CBR drug substrates. We pinpointed a single nucleotide polymorphism in CBR3 (CBR3 V244M) that encodes for a V244 to M244 change. Blacks showed a higher frequency of the M244 allele (q = 0.51, n = 49) than did whites (q = 0.31, n = 70; p = 0.003). In addition, DNA variation panels from 10 ethnic groups presented a wide range of CBR3 V244M genotype distributions. Kinetic experiments with the recombinant CBR3 protein variants and menadione revealed that CBR3 M244 has significantly higher V-max than does CBR3 V244 (V-max CBR3 M244 = 40.6 +/- 1.3 mumol/min . mg versus V-max CBR3 V244 = 19.6 +/- 2.0 mumol/min . mg, p = 0.002). In contrast, both isoforms presented similar K-m values (K-m CBR3 M244 = 22.9 +/- 2.9 muM versus K-m CBR3 V244 = 24.6 +/- 3.2 muM, p = 0.43). Assays with NADP(H) demonstrated a higher V-maxNADP(H) (1.6-fold) and increased catalytic efficiency (V-maxNADP(H)/K-mNADP(H)) for CBR3 M244 compared with CBR3 V244 ( p = 0.013). Comparative three-dimensional analyses based on the structure of the homologous porcine carbonyl reductase suggested that the V244M substitution is positioned in a region critical for interactions with the NADP( H) cofactor. These studies demonstrate that the common CBR3 V244M polymorphism encodes for CBR3 isoforms with distinctive enzymatic properties.
引用
收藏
页码:254 / 257
页数:4
相关论文
共 25 条
[1]   LINKAGE MAPPING OF THE CARBONYL REDUCTASE (CBR) GENE ON HUMAN CHROMOSOME-21 USING A DNA POLYMORPHISM IN THE 3' UNTRANSLATED REGION [J].
AVRAMOPOULOS, D ;
COX, T ;
FORREST, GL ;
CHAKRAVARTI, A ;
ANTONARAKIS, SE .
GENOMICS, 1992, 13 (02) :447-448
[2]   EXPRESSION, CRYSTALLIZATION AND PRELIMINARY CRYSTALLOGRAPHIC ANALYSIS OF HUMAN CARBONYL REDUCTASE [J].
BOHREN, KM ;
WERMUTH, B ;
HARRISON, D ;
RINGE, D ;
PETSKO, GA ;
GABBAY, KH .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 244 (05) :659-664
[3]   INDUCTION OF A HUMAN CARBONYL REDUCTASE GENE LOCATED ON CHROMOSOME-21 [J].
FORREST, GL ;
AKMAN, S ;
KRUTZIK, S ;
PAXTON, RJ ;
SPARKES, RS ;
DOROSHOW, J ;
FELSTED, RL ;
GLOVER, CJ ;
MOHANDAS, T ;
BACHUR, NR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1048 (2-3) :149-155
[4]   Carbonyl reductase [J].
Forrest, GL ;
Gonzalez, B .
CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 129 (1-2) :21-40
[5]   Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia:: Multi-institutional collaborative study [J].
Frost, BM ;
Eksborg, S ;
Björk, O ;
Abrahamsson, J ;
Behrendtz, M ;
Castor, A ;
Forestier, E ;
Lönnerholm, G .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (05) :329-337
[6]   Porcine carbonyl reductase - Structural basis for a functional monomer in short chain dehydrogenases/reductases [J].
Ghosh, D ;
Sawicki, M ;
Pletnev, V ;
Erman, M ;
Ohno, S ;
Nakajin, S ;
Duax, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) :18457-18463
[7]  
HERMANS JJR, 1992, DRUG METAB DISPOS, V20, P268
[8]   CARBONYL REDUCTASE FROM HUMAN TESTIS - PURIFICATION AND COMPARISON WITH CARBONYL REDUCTASE FROM HUMAN BRAIN AND RAT TESTIS [J].
INAZU, N ;
RUEPP, B ;
WIRTH, H ;
WERMUTH, B .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1116 (01) :50-56
[9]  
IWATA N, 1993, BIOCHEM PHARMACOL, V45, P1711
[10]   Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience [J].
Krischer, JP ;
Epstein, S ;
Cuthbertson, DD ;
Goorin, AM ;
Epstein, ML ;
Lipshultz, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1544-1552